Lineweaver Wealth Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.09M Buy
36,357
+1,929
+6% +$111K 0.25% 86
2026
Q1
$2.09M Buy
34,428
+2,056
+6% +$120K 0.28% 75
2025
Q4
$1.75M Sell
32,372
-228
-0.7% -$11K 0.24% 83
2025
Q3
$1.47M Buy
32,600
+3,274
+11% +$153K 0.22% 86
2025
Q2
$1.36M Buy
29,326
+5,121
+21% +$251K 0.21% 84
2025
Q1
$1.48M Buy
24,205
+3,602
+17% +$210K 0.25% 79
2024
Q4
$1.17M Buy
+20,603
New +$1.15M 0.22% 86
2023
Q4
Sell
-20,303
Closed -$1.18M 129
2023
Q3
$1.18M Sell
20,303
-13,238
-39% -$811K 0.34% 57
2023
Q2
$2.15M Sell
33,541
-213
-0.6% -$14.3K 0.61% 38
2023
Q1
$2.34M Buy
33,754
+1,889
+6% +$133K 0.72% 27
2022
Q4
$2.29M Buy
+31,865
New +$2.4M 0.69% 30
2021
Q4
Sell
-4,533
Closed -$268K 135
2021
Q3
$268K Buy
4,533
+799
+21% +$52.6K 0.08% 115
2021
Q2
$249K Buy
+3,734
New +$243K 0.08% 108

Other funds holding BMY

Lineweaver Wealth Advisors's BMY Position: Q2 2026 in Review

Lineweaver Wealth Advisors increased its Bristol-Myers Squibb (BMY) stake by 5.6% in Q2 2026, buying an estimated $111K and bringing the position to 36,357 shares worth $2.09M. The position accounts for 0.25% of the portfolio, ranked #86.

Lineweaver Wealth Advisors first reported a position in BMY in Q2 2021 and has held it in 13 quarters since. The position peaked at $2.34M in Q1 2023. 878 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Lineweaver Wealth Advisors held 36,357 shares of Bristol-Myers Squibb worth $2.09M as of Q2 2026.
  • Lineweaver Wealth Advisors bought 1,929 Bristol-Myers Squibb shares in Q2 2026, an estimated $111K.
  • Bristol-Myers Squibb made up 0.25% of Lineweaver Wealth Advisors's portfolio in Q2 2026, its #86 holding.
  • Lineweaver Wealth Advisors first reported a position in Bristol-Myers Squibb in Q2 2021 and has held it in 13 quarters since.
  • Lineweaver Wealth Advisors's Bristol-Myers Squibb position peaked at $2.34M in Q1 2023.
  • 878 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Lineweaver Wealth Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.